...
首页> 外文期刊>Pharmacological reports: PR >Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression
【24h】

Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression

机译:丙咪嗪和金刚烷胺联合给药对耐药性单相抑郁患者外周血淋巴细胞[3H] 7-OH-DPAT与多巴胺D3受体结合的影响

获取原文

摘要

Treatment of the patients suffering from therapy-resistant unipolar depression with joint administration of imipramine (twice daily, 100–150 mg/day) and amantadine (twice daily, 150 mg/day) for four to six weeks resulted in the significant increase in the binding of [ H]7-OH-DPAT to dopamine D receptors in the peripheral blood lymphocytes. This effect correlated well with the clinical improvement, estimated with Hamilton’s Depression Rating Scale. In the light of the above data, it seems justified to postulate that joint therapy with imipramine and amantadine may be successful in the treatment-resistant unipolar depression.
机译:联合使用丙咪嗪(每天两次,每次100-150 mg /天)和金刚烷胺(每天两次,每次150 mg /天)联合治疗四到六周,对具有治疗耐受性的单相抑郁症患者产生显着增加的[H] 7-OH-DPAT与外周血淋巴细胞多巴胺D受体的结合。根据汉密尔顿的抑郁评估量表,该效果与临床改善密切相关。根据以上数据,似乎有理由推测,用丙咪嗪和金刚烷胺联合治疗可能在治疗难治性单极抑郁症中取得成功。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号